Please login to the form below

Not currently logged in
Email:
Password:

Zarzio

This page shows the latest Zarzio news and features for those working in and with pharma, biotech and healthcare.

Clock ticking on biosimilar Enbrel in US

Clock ticking on biosimilar Enbrel in US

In markets outsider the US - where it is known as Zarzio and has been available since 2006 - Sandoz' drug has captured around a 30% share of the Neupogen market.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics